Your browser doesn't support javascript.
B-Cell Responses to Sars-Cov-2 mRNA Vaccines.
Kardava, Lela; Buckner, Clarisa M; Moir, Susan.
  • Kardava L; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD.
  • Buckner CM; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD.
  • Moir S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD.
Pathog Immun ; 7(2): 93-119, 2022.
Article in English | MEDLINE | ID: covidwho-2265580
ABSTRACT
Most vaccines against viral pathogens protect through the acquisition of immunological memory from long-lived plasma cells that produce antibodies and memory B cells that can rapidly respond upon an encounter with the pathogen or its variants. The COVID-19 pandemic and rapid deployment of effective vaccines have provided an unprecedented opportunity to study the immune response to a new yet rapidly evolving pathogen. Here we review the scientific literature and our efforts to understand antibody and B-cell responses to SARS-CoV-2 vaccines, the effect of SARSCoV-2 infection on both primary and secondary immune responses, and how repeated exposures may impact outcomes.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Pathog Immun Year: 2022 Document Type: Article Affiliation country: Pai.v7i2.550

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Pathog Immun Year: 2022 Document Type: Article Affiliation country: Pai.v7i2.550